Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 years
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | Skin Health and Disease |
| Online Access: | https://doi.org/10.1002/ski2.404 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846146208082427904 |
|---|---|
| author | John E. Harris Amit G. Pandya Mark Lebwohl Iltefat H. Hamzavi Pearl Grimes Alice B. Gottlieb Howard L. Sofen Angela Y. Moore Mingyue Wang Deanna Kornacki Kathleen Butler David Rosmarin |
| author_facet | John E. Harris Amit G. Pandya Mark Lebwohl Iltefat H. Hamzavi Pearl Grimes Alice B. Gottlieb Howard L. Sofen Angela Y. Moore Mingyue Wang Deanna Kornacki Kathleen Butler David Rosmarin |
| author_sort | John E. Harris |
| collection | DOAJ |
| format | Article |
| id | doaj-art-1a70a9b053964dc19db7e2e4dceb7cd6 |
| institution | Kabale University |
| issn | 2690-442X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Skin Health and Disease |
| spelling | doaj-art-1a70a9b053964dc19db7e2e4dceb7cd62024-12-02T04:03:51ZengWileySkin Health and Disease2690-442X2024-12-0146n/an/a10.1002/ski2.404Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 yearsJohn E. Harris0Amit G. Pandya1Mark Lebwohl2Iltefat H. Hamzavi3Pearl Grimes4Alice B. Gottlieb5Howard L. Sofen6Angela Y. Moore7Mingyue Wang8Deanna Kornacki9Kathleen Butler10David Rosmarin11University of Massachusetts Chan Medical School Worcester Massachusetts USAPalo Alto Foundation Medical Group Sunnyvale California USAIcahn School of Medicine at Mount Sinai New York New York USAHenry Ford Medical Center Detroit Michigan USAThe Vitiligo & Pigmentation Institute of Southern California Los Angeles California USAIcahn School of Medicine at Mount Sinai New York New York USADavid Geffen UCLA School of Medicine Los Angeles California USAArlington Research Center Arlington Texas USAIncyte Corporation Wilmington Delaware USAIncyte Corporation Wilmington Delaware USAIncyte Corporation Wilmington Delaware USAIndiana University School of Medicine Indianapolis Indiana USAhttps://doi.org/10.1002/ski2.404 |
| spellingShingle | John E. Harris Amit G. Pandya Mark Lebwohl Iltefat H. Hamzavi Pearl Grimes Alice B. Gottlieb Howard L. Sofen Angela Y. Moore Mingyue Wang Deanna Kornacki Kathleen Butler David Rosmarin Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 years Skin Health and Disease |
| title | Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 years |
| title_full | Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 years |
| title_fullStr | Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 years |
| title_full_unstemmed | Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 years |
| title_short | Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 years |
| title_sort | safety and efficacy of ruxolitinib cream for the treatment of vitiligo a randomised controlled trial secondary analysis at 3 years |
| url | https://doi.org/10.1002/ski2.404 |
| work_keys_str_mv | AT johneharris safetyandefficacyofruxolitinibcreamforthetreatmentofvitiligoarandomisedcontrolledtrialsecondaryanalysisat3years AT amitgpandya safetyandefficacyofruxolitinibcreamforthetreatmentofvitiligoarandomisedcontrolledtrialsecondaryanalysisat3years AT marklebwohl safetyandefficacyofruxolitinibcreamforthetreatmentofvitiligoarandomisedcontrolledtrialsecondaryanalysisat3years AT iltefathhamzavi safetyandefficacyofruxolitinibcreamforthetreatmentofvitiligoarandomisedcontrolledtrialsecondaryanalysisat3years AT pearlgrimes safetyandefficacyofruxolitinibcreamforthetreatmentofvitiligoarandomisedcontrolledtrialsecondaryanalysisat3years AT alicebgottlieb safetyandefficacyofruxolitinibcreamforthetreatmentofvitiligoarandomisedcontrolledtrialsecondaryanalysisat3years AT howardlsofen safetyandefficacyofruxolitinibcreamforthetreatmentofvitiligoarandomisedcontrolledtrialsecondaryanalysisat3years AT angelaymoore safetyandefficacyofruxolitinibcreamforthetreatmentofvitiligoarandomisedcontrolledtrialsecondaryanalysisat3years AT mingyuewang safetyandefficacyofruxolitinibcreamforthetreatmentofvitiligoarandomisedcontrolledtrialsecondaryanalysisat3years AT deannakornacki safetyandefficacyofruxolitinibcreamforthetreatmentofvitiligoarandomisedcontrolledtrialsecondaryanalysisat3years AT kathleenbutler safetyandefficacyofruxolitinibcreamforthetreatmentofvitiligoarandomisedcontrolledtrialsecondaryanalysisat3years AT davidrosmarin safetyandefficacyofruxolitinibcreamforthetreatmentofvitiligoarandomisedcontrolledtrialsecondaryanalysisat3years |